Direct costs and health-related resource utilisation in the 6 months after insulin initiation in German patients with type 2 diabetes mellitus in 2006: INSTIGATE study^*

References

• Definition, diagnosis and classification of diabetes mellitus and its complications: Report of a WHO consultation. World Health Organization, Department of Noncommunicable Disease Surveillance. Geneva, 1999. WHO/NCD/NCS/99.2. Available from http://whqlibdoc.who.int/hq/1999/WHO_NCD_NCS_99.2.pdf, accessed 21 March 20061. Definition, diagnosis and classification of diabetes mellitus and its complications: Report of a WHO consultation. World Health Organization, Department of Noncommunicable Disease Surveillance. Geneva, 1999. WHO/NCD/NCS/99.2. Available from http://whqlibdoc.who.int/hq/1999/WHO_NCD_NCS_99.2.pdf, accessed 21 March 2006
   Google Scholar
• Amos A, McCarty D, Zimmet P. The rising global burden of diabetes and its complications: Estimates and projections to the year 2010. Diabet Med 1997;14 Suppl 5:S1–852. Amos A, McCarty D, Zimmet P. The rising global burden of diabetes and its complications: Estimates and projections to the year 2010. Diabet Med 1997;14 Suppl 5:S1–85
   PubMed Web of Science ®Google Scholar
• Rathmann W, Haastert B, Icks A, et al. High prevalence of undiagnosed diabetes mellitus in Southern Germany: target populations for efficient screening: the KORA survey 2000. Diabetologia 2003;246:182–93. Rathmann W, Haastert B, Icks A, et al. High prevalence of undiagnosed diabetes mellitus in Southern Germany: target populations for efficient screening: the KORA survey 2000. Diabetologia 2003;246:182–9
   Google Scholar
• The German Diabetes Union. Deutscher Gesundheitsbericht Diabetes 2008 [in German] (Health Report on Diabetes in Germany, 2008). Available at http://134.99.12.236/∼nafdm/webseite/upload/Gesundheitsbericht_Diabetes_2008.pdf, retrieved on 12 February 20084. The German Diabetes Union. Deutscher Gesundheitsbericht Diabetes 2008 [in German] (Health Report on Diabetes in Germany, 2008). Available at http://134.99.12.236/∼nafdm/webseite/upload/Gesundheitsbericht_Diabetes_2008.pdf, retrieved on 12 February 2008
   Google Scholar
• Hopkins J. Diabetes a growing problem in the United States. BMJ 2001;322:1945. Hopkins J. Diabetes a growing problem in the United States. BMJ 2001;322:194
   Google Scholar
• Hader C, Beischer W, Braun A, et al. Diagnosis, treatment and follow-up of diabetes mellitus in the elderly. Scherbaum W, Kerner W, eds. German Diabetes Association 2006. Available at: http://www.deutsche-diabetes-gesellschaft.de/redaktion/mitteilungen/leitlinien/GUIDELINE_DM_IN_ELDERLY_05_2004_190906.pdf, retrieved on 11th February 20086. Hader C, Beischer W, Braun A, et al. Diagnosis, treatment and follow-up of diabetes mellitus in the elderly. Scherbaum W, Kerner W, eds. German Diabetes Association 2006. Available at: http://www.deutsche-diabetes-gesellschaft.de/redaktion/mitteilungen/leitlinien/GUIDELINE_DM_IN_ELDERLY_05_2004_190906.pdf, retrieved on 11th February 2008
   Google Scholar
• Schwartz S. Is there a rationale for insulin therapy in pre- diabetic individuals? Treat Endocrinol 2006;5:385–3937. Schwartz S. Is there a rationale for insulin therapy in pre- diabetic individuals? Treat Endocrinol 2006;5:385–393
   Google Scholar
• Young A. Clinical studies. Adv Pharmacol 2005;52:289–3208. Young A. Clinical studies. Adv Pharmacol 2005;52:289–320
   PubMedGoogle Scholar
• Pawaskar M, Camacho F, Anderson R, et al. Health care costs and medication adherence associated with initiation of insulin pen therapy in Medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis. Clin Ther 2007;29:1294–3059. Pawaskar M, Camacho F, Anderson R, et al. Health care costs and medication adherence associated with initiation of insulin pen therapy in Medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis. Clin Ther 2007;29:1294–305
   Web of Science ®Google Scholar
• Brown J, Nichols G, Glauber H, et al. Health care costs associated with escalation of drug treatment in type 2 diabetes mellitus. Am J Health Syst Pharm 2001;58:151–710. Brown J, Nichols G, Glauber H, et al. Health care costs associated with escalation of drug treatment in type 2 diabetes mellitus. Am J Health Syst Pharm 2001;58:151–7
   PubMed Web of Science ®Google Scholar
• Rathmann W, Haastert B, Icks A, et al. Trends in outpatient prescription drug costs in diabetic patients in Germany, 1994–2004. Diabetes Care 2007;30:848–5311. Rathmann W, Haastert B, Icks A, et al. Trends in outpatient prescription drug costs in diabetic patients in Germany, 1994–2004. Diabetes Care 2007;30:848–53
   PubMed Web of Science ®Google Scholar
• Weber C, Neeser K, Wenzel H, et al. [Costs of diabetes mellitus type 2 and self measurement of blood glucose in Germany]. Versicherungsmedizin 2006;58:133–712. Weber C, Neeser K, Wenzel H, et al. [Costs of diabetes mellitus type 2 and self measurement of blood glucose in Germany]. Versicherungsmedizin 2006;58:133–7
   PubMedGoogle Scholar
• Groop L. Insulin resistance: the fundamental trigger of type 2 diabetes. Diabetes Obes Metab 1999;1 Suppl 1:S1–713. Groop L. Insulin resistance: the fundamental trigger of type 2 diabetes. Diabetes Obes Metab 1999;1 Suppl 1:S1–7
   PubMed Web of Science ®Google Scholar
• Kahn S, Hull R, Utzschneider K. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006;444:840–614. Kahn S, Hull R, Utzschneider K. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006;444:840–6
   PubMed Web of Science ®Google Scholar
• Krentz A. Management of type 2 diabetes in the obese patient: current concerns and emerging therapies. Curr Med Res Opin 2008;24:401–1715. Krentz A. Management of type 2 diabetes in the obese patient: current concerns and emerging therapies. Curr Med Res Opin 2008;24:401–17
   PubMed Web of Science ®Google Scholar
• Yu A, Wu E, Birnbaum H, et al. Short-term economic impact of body weight change among patients with type 2 diabetes treatment with antidiabetic agents: analysis using claims, laboratory, and medical record data. Curr Med Res Opin 2007;23:2157–6916. Yu A, Wu E, Birnbaum H, et al. Short-term economic impact of body weight change among patients with type 2 diabetes treatment with antidiabetic agents: analysis using claims, laboratory, and medical record data. Curr Med Res Opin 2007;23:2157–69
   PubMed Web of Science ®Google Scholar
• The Reference Medical Professional Database. Schwarzeck-Verlag GmbH, 2005. Available from http://www.d-medico.de, accessed September 200517. The Reference Medical Professional Database. Schwarzeck-Verlag GmbH, 2005. Available from http://www.d-medico.de, accessed September 2005
   Google Scholar
• German Association of Research-Based Pharmaceutical Companies. Non-interventional studies [in German] 2007. Available at http://www.vfa.de/download/SAVE/de/presse/pressemitteilungen/pm_017_2007_attachments/nis-arten-und-ziele.pdf, accessed February 200818. German Association of Research-Based Pharmaceutical Companies. Non-interventional studies [in German] 2007. Available at http://www.vfa.de/download/SAVE/de/presse/pressemitteilungen/pm_017_2007_attachments/nis-arten-und-ziele.pdf, accessed February 2008
   Google Scholar
• Jonsson B. Revealing the cost of type II diabetes in Europe. Diabetologia 2002;45:S5–1219. Jonsson B. Revealing the cost of type II diabetes in Europe. Diabetologia 2002;45:S5–12
   PubMed Web of Science ®Google Scholar
• Kassenärztliche Bundesvereinigung. Einheitlicher Bewert-ungsmaßstab (EBM) 2006. Deutscher Ärzte-Verlag20. Kassenärztliche Bundesvereinigung. Einheitlicher Bewert-ungsmaßstab (EBM) 2006. Deutscher Ärzte-Verlag
   Google Scholar
• Kassenärztliche Bundesvereinigung. Politisches Aktion-sprogramm der Kassenärzte. Available from http://www.kbv.de/gesundheitspolitik/1365.html, accessed 200621. Kassenärztliche Bundesvereinigung. Politisches Aktion-sprogramm der Kassenärzte. Available from http://www.kbv.de/gesundheitspolitik/1365.html, accessed 2006
   Google Scholar
• Schwabe U, Paffrath D. Arzneimittelverordnungsreport. Berlin, Heidelberg: Springer-Verlag; 200622. Schwabe U, Paffrath D. Arzneimittelverordnungsreport. Berlin, Heidelberg: Springer-Verlag; 2006
   Google Scholar
• Fricke U, Günther J, Zawinell A. Anatomisch-Therapeutisch-Chemische Klassifikation mit Tagesdosen für den deutschen Arzneimittelmarkt herausgegeben vom Wissenschaftlichen Institut der AOK, 4. Auflage. Bonn: 200523. Fricke U, Günther J, Zawinell A. Anatomisch-Therapeutisch-Chemische Klassifikation mit Tagesdosen für den deutschen Arzneimittelmarkt herausgegeben vom Wissenschaftlichen Institut der AOK, 4. Auflage. Bonn: 2005
   Google Scholar
• Nathan D, Cleary P, Backlund J, et al. Intensive diabetes management and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643–5324. Nathan D, Cleary P, Backlund J, et al. Intensive diabetes management and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643–53
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998;352:837–5325. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998;352:837–53
   PubMed Web of Science ®Google Scholar
• Björk S. The cost of diabetes and diabetes care. Diab Res Clin Pract 2001;54:13–1826. Björk S. The cost of diabetes and diabetes care. Diab Res Clin Pract 2001;54:13–18
   PubMed Web of Science ®Google Scholar